A detailed history of Wms Partners, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Wms Partners, LLC holds 3,414 shares of NVO stock, worth $358,674. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,414
Previous 2,871 18.91%
Holding current value
$358,674
Previous $409,000 0.73%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$119.07 - $145.42 $64,655 - $78,963
543 Added 18.91%
3,414 $406,000
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $60,741 - $72,720
-495 Reduced 14.71%
2,871 $409,000
Q1 2024

May 15, 2024

BUY
$102.11 - $135.92 $24,914 - $33,164
244 Added 7.82%
3,366 $432,000
Q4 2023

Feb 12, 2024

SELL
$87.78 - $105.45 $119,205 - $143,201
-1,358 Reduced 30.31%
3,122 $322,000
Q3 2023

Nov 09, 2023

BUY
$90.94 - $199.54 $204,887 - $449,563
2,253 Added 101.17%
4,480 $407,000
Q1 2023

May 12, 2023

BUY
$132.34 - $159.14 $132 - $159
1 Added 0.04%
2,227 $354,000
Q4 2022

Feb 07, 2023

SELL
$102.55 - $135.33 $148,184 - $195,551
-1,445 Reduced 39.36%
2,226 $301,000
Q3 2022

Nov 08, 2022

SELL
$95.28 - $116.93 $392,363 - $481,517
-4,118 Reduced 52.87%
3,671 $366,000
Q2 2022

Aug 05, 2022

BUY
$103.24 - $121.81 $526,524 - $621,231
5,100 Added 189.66%
7,789 $868,000
Q1 2022

May 10, 2022

BUY
$93.1 - $112.54 $250,345 - $302,620
2,689 New
2,689 $299,000
Q4 2018

Feb 14, 2019

SELL
$41.54 - $47.25 $198,561 - $225,855
-4,780 Closed
0 $0
Q1 2018

May 14, 2018

SELL
$48.49 - $58.14 $388,889 - $466,282
-8,020 Reduced 62.66%
4,780 $235,000
Q3 2017

Oct 27, 2017

SELL
$41.15 - $49.22 $823 - $984
-20 Reduced 0.16%
12,800 $616,000
Q2 2017

Aug 09, 2017

BUY
N/A
12,820
12,820 $550,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Wms Partners, LLC Portfolio

Follow Wms Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wms Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wms Partners, LLC with notifications on news.